CDT Increases Stake in Sarborg following its Quantum Computing and Intellectual Property Expansion

CDT Announces Investment in Pep'd, Expanding into the Fast-Growing US Peptide Market

CDT Validates Enhanced Solid-Form Properties Within Its IP Portfolio

CDT Appoints Co-Founder James Bligh as Chief Executive Officer to Lead Next Phase of Growth

CDT Provides Capital Update and Confirms No Nasdaq Deficiencies

CDT Highlights Sarborg’s Application of Signature Intelligence and Quantum Computing Models to Mental Health

CDT Partners with QIMA Life Sciences to Evaluate Novel Tapinarof Combinations in Psoriasis and Vitiligo

CDT Highlights Sarborg’s Expanding Quantum Computing IP Portfolio and Application to Drug Discovery

CDT Highlights Sarborg's Solid-Form Patent Filing on a First-in-Class Respiratory Asset

CDT Equity Inc. Announces Reverse Stock Split